Gaetano Leto

Type 2 diabetes remission after initiation of GLP-1 receptor agonists: frequency, characteristics, and outcomes using multiple definitions in an observational study

Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk

Short-term effectiveness of dapagliflozin versus DPP-4 inhibitors in elderly patients with type 2 diabetes: a multicentre retrospective study

Development of a clinical risk score to predict death in patients with COVID‐19

Effects of the <scp>COVID</scp> ‐19 lockdown on glycaemic control in subjects with type 2 diabetes: the glycalock study

Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care

Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II)

Clinical features of patients with type 2 diabetes with and without Covid-19: A case control study (CoViDiab I)

Serum Sclerostin and Bone Turnover in Latent Autoimmune Diabetes in Adults

Sclerostin is expressed in the atherosclerotic plaques of patients who undergoing carotid endarterectomy

Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes)